Bessemer Group
VNDA icon

Bessemer Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Bessemer Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-718
Closed -$3K – 2215
2023
Q4 		$3K Hold
718
– – ﹤0.01% 1980
2023
Q3 		$3K Buy
+718
New +$3.99K ﹤0.01% 1921
2020
Q3 		– Sell
-49,200
Closed -$563K – 1679
2020
Q2 		$563K Buy
+49,200
New +$557K ﹤0.01% 936
2019
Q4 		– Sell
-75
Closed -$1K – 1768
2019
Q3 		$1K Buy
75
+39
+108% +$544 ﹤0.01% 1689
2019
Q2 		$1K Buy
+36
New +$573 ﹤0.01% 1610

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bessemer Group's VNDA Position: Q1 2024 in Review

Bessemer Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 718 shares — an estimated $3K sold.

Bessemer Group first reported a position in VNDA in Q2 2019 and held it in 5 quarters. The position peaked at $563K in Q2 2020. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Bessemer Group reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Bessemer Group sold 718 Vanda Pharmaceuticals shares in Q1 2024, an estimated $3K.
  • Bessemer Group first reported a position in Vanda Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Bessemer Group's Vanda Pharmaceuticals position peaked at $563K in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Bessemer Group's 13F filing for Q1 2024, filed 13 May 2024.